Cell immunotherapy infusing HLA-haploidentical lymphocytes from a family member of non-HSCT donor

Cell immunotherapy infusing HLA-haploidentical lymphocytes from a family member of non-HSCT donor - HLA-haploidentical lymphocyte infusion from a family member of non-HSCT donor

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014236

Enrollment

Registered

2014-06-12

Start date

2013-07-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed malignancies or refractory viral diseases after allogeneic hematopoietic stem cell transplantation

Interventions

Cell immunotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Fulfilling the criteria mentioned above. 2. Written consent was obtained.

Exclusion criteria

Exclusion criteria: 1. Acute GVHD Grade II or above. 2. Extensive chronic GVHD. 3. Physician's decision.

Design outcomes

Primary

Measure	Time frame
Maximum tolerable dose of T-cell infusion	—

Countries

Japan

Contacts

Public ContactAkihisa Sawada

Osaka medical center and research institute for maternal and child health Hematology/Oncology

asawada@mch.pref.osaka.jp0725-56-1220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026